- Home
- LFCR vs OCGN Comparison
LFCR vs OCGN Comparison
Compare LFCR & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- OCGN
- Stock Information
- Founded
- LFCR 1986
- OCGN 2013
- Country
- LFCR United States
- OCGN United States
- Employees
- LFCR N/A
- OCGN N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFCR Health Care
- OCGN Health Care
- Exchange
- LFCR Nasdaq
- OCGN Nasdaq
- Market Cap
- LFCR 214.7M
- OCGN 229.2M
- IPO Year
- LFCR N/A
- OCGN N/A
- Fundamental
- Price
- LFCR $6.29
- OCGN $0.81
- Analyst Decision
- LFCR Buy
- OCGN Strong Buy
- Analyst Count
- LFCR 3
- OCGN 3
- Target Price
- LFCR $8.00
- OCGN $5.67
- AVG Volume (30 Days)
- LFCR 377.7K
- OCGN 5.0M
- Earning Date
- LFCR 01-02-2025
- OCGN 11-08-2024
- Dividend Yield
- LFCR N/A
- OCGN N/A
- EPS Growth
- LFCR N/A
- OCGN N/A
- EPS
- LFCR N/A
- OCGN N/A
- Revenue
- LFCR $130,858,000.00
- OCGN $4,700,000.00
- Revenue This Year
- LFCR $2.24
- OCGN N/A
- Revenue Next Year
- LFCR $7.88
- OCGN N/A
- P/E Ratio
- LFCR N/A
- OCGN N/A
- Revenue Growth
- LFCR 16.47
- OCGN N/A
- 52 Week Low
- LFCR $3.68
- OCGN $0.50
- 52 Week High
- LFCR $8.90
- OCGN $2.11
- Technical
- Relative Strength Index (RSI)
- LFCR 42.13
- OCGN 45.48
- Support Level
- LFCR $6.13
- OCGN $0.73
- Resistance Level
- LFCR $6.67
- OCGN $1.00
- Average True Range (ATR)
- LFCR 0.42
- OCGN 0.06
- MACD
- LFCR -0.04
- OCGN 0.00
- Stochastic Oscillator
- LFCR 25.98
- OCGN 25.31
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").